Good morning, and thank you for joining us to discuss YETI Holdings' fourth quarter and fiscal 2024 results. Leading the call ...
Aytu BioPharma reported a decrease in net revenue for Q2 2025, reflecting challenges in its ADHD portfolio. Despite this, the company posted a net income of $800,000, translating to $0.13 per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback